secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001193125-24-051235
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharma reports record 2023 revenue of $398.2M (+85.9% YoY); non-GAAP EPS $1.96
--------------------------------------------------------------------------------

- Q4 2023 total revenue $110.6M (+82% YoY); full-year GAAP net income $71.4M ($0.63 diluted).
- Non-GAAP net income $223.2M ($1.96 diluted) vs. $113.9M ($1.02) in 2022, up 96%.
- FIRDAPSE net revenue $258.4M (+20.8%); FYCOMPA contributed $138.1M since acquisition.
- AGAMREE FDA approval for Duchenne MD; commercial launch on track for Q1 2024.
- FY2024 total revenue guidance $455M-$475M, implying ~14-19% growth vs. 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312524051235/0001193125-24-051235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312524051235/d776053d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-051235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer